ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,569.40
-1.24%
S&P ASX All Technology
2,973.30
-1.38%
Brent Oil
85.60
-0.34%
US Dollar vs AUD
1.54607
0.12%
Bitcoin
60,160.66
-0.73%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Nanobiotix (NANO)

  7. Nanobiotix (NANO) News

NANO

Nanobiotix (NANO)

Nanobiotix
Date:
Sort by:
 Showing the most relevant articles for your search:EU:NANO
DateTimeSourceHeadlineSymbolCompany
11/07/202308:37Dow Jones NewsADRs End Mostly Lower, Nanobiotix and Taiwan Semiconductor Manufacturing Trade ActivelyEU:NANONanobiotix
10/07/202321:37Dow Jones NewsECHO BOURSE: Nanobiotix bondit de 51% après un accord de licence avec JanssenEU:NANONanobiotix
10/07/202320:57Dow Jones NewsNanobiotix Shares Soar on Licensing Deal With J&J UnitEU:NANONanobiotix
06/05/202303:11Dow Jones NewsECHO BOURSE: Nanobiotix en négociation avec un grand laboratoire, l'action s'envoleEU:NANONanobiotix
06/05/202303:06Dow Jones NewsECHO BOURSE: Nanobiotix en négociation avec un grand laboratoire, l'action s'envoleEU:NANONanobiotix
10/07/201904:45GlobeNewswire Inc.Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet OncologyEU:NANONanobiotix
01/07/201916:00GlobeNewswire Inc.Nanobiotix announces new organizational structure as the company enters its next stage after first european market approvalEU:NANONanobiotix
04/06/201916:00GlobeNewswire Inc.NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVALEU:NANONanobiotix
28/05/201915:00GlobeNewswire Inc.Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcareEU:NANONanobiotix
05/04/201903:31GlobeNewswire Inc.Nanobiotix Announces First Ever Radioenhancer to Receive European Market ApprovalEU:NANONanobiotix
03/04/201903:56GlobeNewswire Inc.Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pr...EU:NANONanobiotix
26/03/201918:00GlobeNewswire Inc.Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedbackEU:NANONanobiotix
16/03/201904:40GlobeNewswire Inc.Nanobiotix 2018 Annual ResultsEU:NANONanobiotix
15/11/201823:00GlobeNewswire Inc.Nanobiotix revenues for the 3rd quarter of 2018EU:NANONanobiotix
19/10/201823:05GlobeNewswire Inc.NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMOEU:NANONanobiotix
16/10/201813:13GlobeNewswire Inc.Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment BankEU:NANONanobiotix
26/09/201812:00GlobeNewswire Inc.Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (S...EU:NANONanobiotix
20/09/201812:04GlobeNewswire Inc.Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018EU:NANONanobiotix
05/09/201802:20GlobeNewswire Inc.NANOBIOTIX half year results for the six months ended June 30, 2018EU:NANONanobiotix
27/07/201802:32GlobeNewswire Inc.NANOBIOTIX signs a 40 M€ non-dilutive financing agreement with the European Investment BankEU:NANONanobiotix
22/06/201822:29Dow Jones NewsNanobiotix offre un succès bienvenu pour relancer les biotechs tricolores - DJ PlusEU:NANONanobiotix
22/06/201803:41GlobeNewswire Inc.NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3EU:NANONanobiotix
06/06/201823:55GlobeNewswire Inc.NANOBIOTIX' Management statement on recent share price variationEU:NANONanobiotix
14/05/201816:57Cercle FinanceCalendrier des sociétés sur 15 joursEU:NANONanobiotix
04/05/201803:35GlobeNewswire Inc.Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathwa...EU:NANONanobiotix
18/04/201804:01GlobeNewswire Inc.AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING path...EU:NANONanobiotix
11/04/201817:01Cercle FinanceNanobiotix: projet de recherche avec le MD AndersonEU:NANONanobiotix
11/04/201804:42GlobeNewswire Inc.NANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-...EU:NANONanobiotix
31/03/201801:03GlobeNewswire Inc.NANOBIOTIX : Nanobiotix 2017 Annual ResultsEU:NANONanobiotix
26/03/201818:12Cercle FinanceCalendrier des sociétés sur 15 joursEU:NANONanobiotix
 Showing the most relevant articles for your search:EU:NANO

Your Recent History

ASX
RIO
Rio Tinto
ASX
WES
Wesfarmers
NASDAQ
AMZN
Amazon.com
ASX
WDC
Westfield
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
ASX
XJO
S&P ASX 200
NYSE
DIS
Walt Disney
ASX
SUN
Suncorp
ASX
BHP
BHP
ASX
ANZ
Australia And New Zealan...
NASDAQ
GOOGL
Alphabet
ASX
CBA
Commonwealth Bank Of Aus...
NASDAQ
MSFT
Microsoft
NYSE
XOM
Exxon Mobil
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved